People born with inherited high cholesterol — known as the “evil cousin” — may soon have access to new and potentially ...

Eli Lilly's muvalaplin Phase 2 trial showed significant Lp(a) reduction, meeting primary and secondary endpoints with ...

Eli Lilly LLY announced that its investigational oral, once-daily cholesterol-lowering drug muvalaplin reduced lipoprotein(a) ...

Excess cholesterol is known to form artery-clogging plaques that can lead to stroke, arterial disease, heart attack, and more, making it the focus of many heart health campaigns.

Dr Eric Berg DC is a ketosis and intermittent fasting expert, and he has shared the many benefits of turmeric, as well as how ...

Since the discovery of statins and the Scandinavian Simvastatin Survival Study (4S) results three decades ago, remarkable advances have been made in the treatment of dyslipidaemia, a major risk factor ...

The pharmaceutical giant presented mid-stage trial data on the pill, muvalaplin, at the American Heart Association Scientific ...

Dr Eric Berg DC, who is known as The Knowledge Doc, has shared the 'amazing benefits' of taking half a teaspoon of a ...

At AHA, Phase 2 results from Eli Lilly and Silence Therapeutics are seen as signs of a "major new path" of cardiovascular ...

Lilly’s muvalaplin is the first oral drug to show positive Phase II findings for Lp(a) reduction, eliciting up to an 86% drop ...

An experimental oral drug called muvalaplin shows promise in reducing the cholesterol linked to heart disease in a study.